These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

718 related articles for article (PubMed ID: 25640408)

  • 1. Risk factors for progressive myopia in the atropine therapy for myopia study.
    Loh KL; Lu Q; Tan D; Chia A
    Am J Ophthalmol; 2015 May; 159(5):945-9. PubMed ID: 25640408
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Atropine for the treatment of childhood myopia: changes after stopping atropine 0.01%, 0.1% and 0.5%.
    Chia A; Chua WH; Wen L; Fong A; Goon YY; Tan D
    Am J Ophthalmol; 2014 Feb; 157(2):451-457.e1. PubMed ID: 24315293
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Atropine for the treatment of childhood myopia: effect on myopia progression after cessation of atropine.
    Tong L; Huang XL; Koh AL; Zhang X; Tan DT; Chua WH
    Ophthalmology; 2009 Mar; 116(3):572-9. PubMed ID: 19167081
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Atropine for the treatment of childhood myopia: safety and efficacy of 0.5%, 0.1%, and 0.01% doses (Atropine for the Treatment of Myopia 2).
    Chia A; Chua WH; Cheung YB; Wong WL; Lingham A; Fong A; Tan D
    Ophthalmology; 2012 Feb; 119(2):347-54. PubMed ID: 21963266
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Two-Year Clinical Trial of the Low-Concentration Atropine for Myopia Progression (LAMP) Study: Phase 2 Report.
    Yam JC; Li FF; Zhang X; Tang SM; Yip BHK; Kam KW; Ko ST; Young AL; Tham CC; Chen LJ; Pang CP
    Ophthalmology; 2020 Jul; 127(7):910-919. PubMed ID: 32019700
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low-Concentration Atropine for Myopia Progression (LAMP) Study: A Randomized, Double-Blinded, Placebo-Controlled Trial of 0.05%, 0.025%, and 0.01% Atropine Eye Drops in Myopia Control.
    Yam JC; Jiang Y; Tang SM; Law AKP; Chan JJ; Wong E; Ko ST; Young AL; Tham CC; Chen LJ; Pang CP
    Ophthalmology; 2019 Jan; 126(1):113-124. PubMed ID: 30514630
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of low-dose atropine on myopia progression, pupil diameter and accommodative amplitude: low-dose atropine and myopia progression.
    Fu A; Stapleton F; Wei L; Wang W; Zhao B; Watt K; Ji N; Lyu Y
    Br J Ophthalmol; 2020 Nov; 104(11):1535-1541. PubMed ID: 32086237
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of Changes in Refraction and Biometry of Atropine- and Placebo-Treated Eyes.
    Kumaran A; Htoon HM; Tan D; Chia A
    Invest Ophthalmol Vis Sci; 2015 Aug; 56(9):5650-5. PubMed ID: 26313301
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential Effects on Ocular Biometrics by 0.05%, 0.025%, and 0.01% Atropine: Low-Concentration Atropine for Myopia Progression Study.
    Li FF; Kam KW; Zhang Y; Tang SM; Young AL; Chen LJ; Tham CC; Pang CP; Yam JC
    Ophthalmology; 2020 Dec; 127(12):1603-1611. PubMed ID: 32525048
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevention of myopia onset with 0.025% atropine in premyopic children.
    Fang PC; Chung MY; Yu HJ; Wu PC
    J Ocul Pharmacol Ther; 2010 Aug; 26(4):341-5. PubMed ID: 20698798
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 0.01% Atropine Eye Drops in Children With Myopia and Intermittent Exotropia: The AMIXT Randomized Clinical Trial.
    Wang Z; Li T; Zuo X; Zhang T; Liu L; Zhou C; Leng Z; Chen X; Wang L; Wang X; Liu H
    JAMA Ophthalmol; 2024 Aug; 142(8):722-730. PubMed ID: 38958962
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Topical atropine in retarding myopic progression and axial length growth in children with moderate to severe myopia: a pilot study.
    Fan DS; Lam DS; Chan CK; Fan AH; Cheung EY; Rao SK
    Jpn J Ophthalmol; 2007; 51(1):27-33. PubMed ID: 17295137
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of 1% atropine eye drops in retarding progressive axial myopia in Indian eyes.
    Kothari M; Rathod V
    Indian J Ophthalmol; 2017 Nov; 65(11):1178-1181. PubMed ID: 29133646
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Atropine treatment for myopia.
    Brown SM
    Ophthalmology; 2009 Oct; 116(10):2040; author reply 2040-1. PubMed ID: 19800530
    [No Abstract]   [Full Text] [Related]  

  • 15. Age Effect on Treatment Responses to 0.05%, 0.025%, and 0.01% Atropine: Low-Concentration Atropine for Myopia Progression Study.
    Li FF; Zhang Y; Zhang X; Yip BHK; Tang SM; Kam KW; Young AL; Chen LJ; Tham CC; Pang CP; Yam JC
    Ophthalmology; 2021 Aug; 128(8):1180-1187. PubMed ID: 33422558
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and Efficacy of Low-Dose Atropine Eyedrops for the Treatment of Myopia Progression in Chinese Children: A Randomized Clinical Trial.
    Wei S; Li SM; An W; Du J; Liang X; Sun Y; Zhang D; Tian J; Wang N
    JAMA Ophthalmol; 2020 Nov; 138(11):1178-1184. PubMed ID: 33001210
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Atropine for the treatment of childhood myopia.
    Chua WH; Balakrishnan V; Chan YH; Tong L; Ling Y; Quah BL; Tan D
    Ophthalmology; 2006 Dec; 113(12):2285-91. PubMed ID: 16996612
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Five-Year Clinical Trial on Atropine for the Treatment of Myopia 2: Myopia Control with Atropine 0.01% Eyedrops.
    Chia A; Lu QS; Tan D
    Ophthalmology; 2016 Feb; 123(2):391-399. PubMed ID: 26271839
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of parental myopia in the progression of myopia and its interaction with treatment in COMET children.
    Kurtz D; Hyman L; Gwiazda JE; Manny R; Dong LM; Wang Y; Scheiman M;
    Invest Ophthalmol Vis Sci; 2007 Feb; 48(2):562-70. PubMed ID: 17251451
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The long-term results of using low-concentration atropine eye drops for controlling myopia progression in schoolchildren.
    Wu PC; Yang YH; Fang PC
    J Ocul Pharmacol Ther; 2011 Oct; 27(5):461-6. PubMed ID: 21815829
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 36.